Cormorant Asset Management’s Connect Biopharma Holdings CNTB Stock Holding History

Cormorant Asset Management’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200,000	Closed	-$1.03M	–	81
2021 Q4	$1.03M	Sell	200,000 -300,000	-60%	-$3.33M	0.06%	72
2021 Q3	$11.9M	Sell	500,000 -150,000	-23%	-$3.39M	0.49%	50
2021 Q2	$12.7M	Sell	650,000 -350,000	-35%	-$5.84M	0.43%	54
2021 Q1	$18.5M	Buy	+1,000,000	New	+$17M	0.41%	55

Other funds holding CNTB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cormorant Asset Management's CNTB Position: Q1 2022 in Review

Cormorant Asset Management sold out of Connect Biopharma Holdings (CNTB) in Q1 2022, closing a stake of 200,000 shares — an estimated $1.03M sold.

Cormorant Asset Management first reported a position in CNTB in Q1 2021 and held it in 4 quarters. The position peaked at $18.5M in Q1 2021. 28 funds tracked by Wall St. Rank hold CNTB as of Q1 2022.

Cormorant Asset Management reported no remaining Connect Biopharma Holdings position as of Q1 2022 after selling out during the quarter.
Cormorant Asset Management sold 200,000 Connect Biopharma Holdings shares in Q1 2022, an estimated $1.03M.
Cormorant Asset Management first reported a position in Connect Biopharma Holdings in Q1 2021 and held it in 4 quarters.
Cormorant Asset Management's Connect Biopharma Holdings position peaked at $18.5M in Q1 2021.
28 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2022.

Based on Cormorant Asset Management's 13F filing for Q1 2022, filed 16 May 2022.